Restoring precision when the details matter most.
The largest Phase III trial to date in patients with high-volume cognitive load, evaluating DEMOZUMAB in 847 adults with moderate-to-severe CDF.
Proportion of participants achieving Sustained Detail Recognition (SDR-50) at Week 12, defined as ≥50% improvement in error detection rate during standardised assessment tasks.
DEMOZUMAB demonstrated statistically significant superiority vs placebo in restoring detail recognition capacity in patients with documented precision decline.
Explore full efficacy data →CDF affects professionals across high-precision roles. Consider DEMOZUMAB for patients experiencing cognitive load challenges.
Managing increasing review volumes while maintaining accuracy standards. Noticing more missed inconsistencies in late-afternoon sessions.
Explore efficacy in high-volume CDFExperiencing longer review times and reduced confidence after extended assessment sessions. Concerned about maintaining quality.
Explore mechanism of actionAdapting to greater detail responsibility with less processing time. Seeking support for sustained precision during peak workloads.
Explore dosing flexibilityProven efficacy. Targeted mechanism. Convenient monthly dosing.
64% SDR-50 response at Week 12 in the CLARITY-1 trial, with sustained response through Week 24.
See efficacy dataSelective CFR-1 inhibition addresses the underlying receptor dysregulation, not just symptoms.
Understand MOAOnce-monthly subcutaneous injection. Pre-filled pen available for self-administration.
View dosing guideAccess prescribing information, clinical trial data, and patient resources.
View resources